Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-02-07
DOI
10.3389/fimmu.2020.00125
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
- (2019) Sanjeevani Arora et al. ADVANCES IN THERAPY
- Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
- (2019) Antonio Santaniello et al. Cancers
- Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review
- (2018) Feifei Teng et al. CANCER LETTERS
- PD-L1 Expression Heterogeneity in Non–Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections
- (2018) Enrico Munari et al. Journal of Thoracic Oncology
- The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma
- (2018) Anton Uryvaev et al. MEDICAL ONCOLOGY
- The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC
- (2018) Giulia Mazzaschi et al. LUNG CANCER
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
- (2017) Alice O. Kamphorst et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Human CD39hi regulatory T cells present stronger stability and function under inflammatory conditions
- (2016) Jian Gu et al. Cellular & Molecular Immunology
- Emerging Opportunities and Challenges in Cancer Immunotherapy
- (2016) T. L. Whiteside et al. CLINICAL CANCER RESEARCH
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
- (2016) Alena Gros et al. NATURE MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Value of PD-L1 Testing in Non–Small-Cell Lung Cancer
- (2016) Aaron Lisberg et al. JAMA Oncology
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
- (2015) Dalil Hannani et al. CELL RESEARCH
- Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses
- (2015) Nikhil S. Joshi et al. IMMUNITY
- iTreg induced from CD39+ naive T cells demonstrate enhanced proliferate and suppressive ability
- (2015) Yunjie Lu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
- (2013) Nienke van Rooij et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started